C
GILD icon

CEDRUS’s Gilead Sciences GILD Stock Holding History

CEDRUS’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,654
Closed -$377K – 156
2023
Q4 		$377K Buy
4,654
+400
+9% +$31.1K 0.23% 93
2023
Q3 		$319K Sell
4,254
-630
-13% -$48.5K 0.23% 100
2023
Q2 		$376K Sell
4,884
-305
-6% -$24.3K 0.27% 77
2023
Q1 		$431K Buy
5,189
+248
+5% +$20.5K 0.3% 68
2022
Q4 		$424K Buy
4,941
+220
+5% +$17.4K 0.34% 62
2022
Q3 		$291K Buy
4,721
+1,104
+31% +$69.6K 0.27% 78
2022
Q2 		$224K Buy
+3,617
New +$224K 0.22% 111

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CEDRUS's GILD Position: Q1 2024 in Review

CEDRUS sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 4,654 shares — an estimated $377K sold.

CEDRUS first reported a position in GILD in Q2 2022 and held it in 7 quarters. The position peaked at $431K in Q1 2023. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • CEDRUS reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • CEDRUS sold 4,654 Gilead Sciences shares in Q1 2024, an estimated $377K.
  • CEDRUS first reported a position in Gilead Sciences in Q2 2022 and held it in 7 quarters.
  • CEDRUS's Gilead Sciences position peaked at $431K in Q1 2023.
  • 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on CEDRUS's 13F filing for Q1 2024, filed 15 Apr 2024.